360° SearchNetwork Hot Spots Trends Time Series

Advanced Search Options >>

Biotime Inc

Type: Company

Name: Biotime Inc

First reported 21 hours ago - Updated 21 hours ago - 1 reports

BNP Paribas SA

BNP ups Biostime (01112) target price to $49.2

(Infocast News) BNP Paribas said in its research report that it has lifted Biotime International's (01112) target price from HK$47.5 to HK$49.2 and maintained the "Buy" rating.The brokerage said that it is assured of the quality of Biostime's products ... [Published InfocastFN.com - 21 hours ago]

Entities: Biostime International Holdings Ltd, Biotime Inc, Food Safety, BNP Paribas SA

First reported Jun 17 2013 - Updated Jun 17 2013 - 1 reports

BioTime Elects Henry Nordhoff to Its Board

BioTime, Inc. announced that Henry L. Nordhoff, former CEO and Chairman of Gen-Probe Inc., has been appointed to its Board of Directors. "We are pleased to welcome an accomplished healthcare executive of Hank's caliber to BioTime's board," said Alfred ... [Published Individual.com - Jun 17 2013]

Entities: Biotime Inc, Gen-Probe Inc, American Biogenetic Sciences Inc, Sterling Drug, Immune Response Corporation

First reported Jun 13 2013 - Updated Jun 13 2013 - 1 reports

Private offering nets regenerative medicine company [BioTime] $8.7mm

Home » Blogs » Selected investors have agreed to buy 2.2mm in [BioTime Inc.] (pluripotent stem cell technologies and research products including cell lines, culture media, and hydrogels) common stock, netting the company $8.7mm. BioTime sold the shares ... [Published BioPortfolio - Jun 13 2013]

Entities: Biotime Inc, Regenerative Medicine, pluripotent stem cell, Biotechnology

First reported Jun 12 2013 - Updated Jun 12 2013 - 1 reports

Have the “go bag” ready – killer days are here

The 6 W’s: Who, what, where, when, why and what of itThe RegMed stocks suffering from reversals of fortune … little or no news that has led to one thing only … high volatility. This current ‘condition’ in the RegMed sector is a confidence killer and this ... [Published Proactive Investors USA - Jun 12 2013]

Entities: TRADING RANGE, Gen-Probe Inc, Stem Cell, Cell Lines

First reported Jun 12 2013 - Updated Jun 12 2013 - 1 reports

BioTime raises $9.06 million in registered direct offering of common stock

BioTime, Inc., a US-based biotechnology company, has sold up to an aggregate of 2,180,016 common shares and 545,004 warrants to purchase common shares, in 'units' with each unit consisting of one common share and one-quarter of a warrant, at an offering ... [Published Individual.com - Jun 12 2013]

Entities: Biotime Inc, Common Shares, Offering Price, LifeMap Sciences Inc, warrants

First reported Jun 12 2013 - Updated Jun 12 2013 - 1 reports

BioTime Appoints Henry L. Nordhoff to Board of Directors

Home » Press Releases » BioTime, Inc. (NYSE MKT: BTX) today announced that Henry L. Nordhoff, former CEO and Chairman of Gen-Probe Inc., has been appointed to its Board of Directors.“We are pleased to welcome an accomplished healthcare executive of Hank's ... [Published BioPortfolio - Jun 12 2013]

Entities: Biotime Inc, Gen-Probe Inc, Stem Cell, Regenerative Medicine

First reported Jun 12 2013 - Updated Jun 12 2013 - 1 reports

BioTime Secures $9 Million in Financing

BioTime, Inc. announced that it has closed the equity financing it announced on June 3, and received gross proceeds of $9,057,966. According to a release, BioTime intends to use the net proceeds from the sale of its common shares and warrants for working ... [Published Individual.com - Jun 12 2013]

Entities: Biotime Inc, LifeMap Sciences Inc, Blood Plasma, Regenerative Medicine

First reported Jun 07 2013 - Updated Jun 07 2013 - 2 reports

BioTime (NYSE MKT: BTX) Closes on $9 M Financing

Running to the open markets, get the cash while they … can!BTX has closed the equity financing it announced on 6/3/13 and received gross proceeds of $9,057,966.The common shares and warrants, and the shares issuable upon exercise of the warrants, were ... [Published Proactive Investors USA - Jun 07 2013]

Entities: Biotime Inc, New York Stock Exchange, warrants, Registration Statement

First reported Jun 04 2013 - Updated Jun 04 2013 - 2 reports

BioTime (NYSE MKT: BTX) to Raise $9 M

In Registered Direct OfferingBTX will sell up to an aggregate of 2,180,016 common shares and 545,004 warrants to purchase common shares, in “units” with each unit consisting of one common share and one-quarter of a warrant, at an offering price of $4.155 ... [Published Proactive Investors USA - Jun 04 2013]

Entities: Biotime Inc, Common Shares, warrants, New York Stock Exchange

First reported May 23 2013 - Updated May 24 2013 - 2 reports

BioTime (NYSE MKT: BTX) Shareholders approve Geron assets acquisition

Shareholders approve proposals of acquisition of stem cell assetsBTX’s Special Shareholder Meeting held on 5/21/13 approved the proposals related to the planned acquisition of stem cell related assets from GERN by BTX’s subsidiary Asterias Biotherapeutics. ... [Published Proactive Investors USA - May 24 2013]

Entities: Geron Corp, Biotime Inc, Acquisition

First reported May 23 2013 - Updated May 23 2013 - 2 reports

3 Merger and Acquisitions Stock Stories For a Thursday Appraisal

Elan Corporation ( NYSE:ELN ): Current price $12.39On Thursday, Elan announced that its board as decided that the privately-held investment firm Royalty Pharma’s revised offer as of May 20, to purchase all of Elan’s shares at $12.50 through its shell ... [Published Wall St. Cheat Sheet - May 23 2013]

Entities: Royalty Pharma Management LLC, Élan Corporation plc, Fidelity National Financial Inc, Mergers & Acquisitions

First reported May 20 2013 - Updated May 21 2013 - 3 reports

BioTime (BTX) CEO Dr. Michael West to Present at University of Southern California Minisymposium: Musculoskeletal Development and Repair

Staying up-to-date has never been simpler. Sign up for the today! BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. ... [Published BioSpace - May 21 2013]

Entities: Biotime Inc, Michael West, musculoskeletal, University of Southern California

Quotes

...to welcome an accomplished healthcare executive of Hank's caliber to BioTime's board," said Alfred D Kingsley, Chairman of the Board of BioTime. "Hank's 43 years of experience in the pharmaceutical business, including most recently his leadership role in managing impressive growth at Gen-Probe over a 15-year period should prove valuable as BioTime continues to pursue multiple growth opportunities."

BioTime Elects Henry Nordhoff to Its Board [Published Individual.com - Jun 17 2013]

Report Published: "BioTime Inc. (BTX) - Medical Equipment - Deals and Alliances Profile"

Report Published: "BioTime, Inc. (BTX) - Medical Equipment - Deals and Alliances Profile" [Published Live-PR.com - Jun 10 2013]

...a new tool to help fight the global obesity epidemic," said Dominic P Behan, Ph D , Arena's Executive Vice President and Chief Scientific Officer. "We are proud to provide physicians in the United States with a new treatment option that along with diet and exercise can help committed patients effectively manage their weight."

Arena Reports on Launch of BELVIQ (lorcaserin HCl) CIV for Chronic Weight Management in Adults; G ... [Published BioMedReports - Jun 08 2013]

..." Mr. Silver also states, "According to a recent Reuters poll, U S money management firms increased their holdings of stocks in May for the first time in four months, helping propel a global market rally that sent the benchmark S&P 500 to a series of record highs."

Vista Partners Publishes June 2013 Macroeconomic & Investment Newsletter [Published Stockhouse Canada - Jun 04 2013]

More Content

sort by: Date \| Relevance
Standard Operating Procedure – offerings enhanc... [Published Proactive Investors USA - 8 hours ago]
BNP ups Biostime (01112) target price to $49.2 [Published InfocastFN.com - 21 hours ago]
Feeling the love – for the moment [Published Proactive Investors USA - Jun 17 2013]
BioTime Elects Henry Nordhoff to Its Board [Published Individual.com - Jun 17 2013]
Once You Start Up Financings of the Fortnight, ... [Published The IN VIVO Blog - Jun 14 2013]
The Early Movers – who’s hot, who’s not - MCV5H... [Published Proactive Investors USA - Jun 13 2013]
Private offering nets regenerative medicine com... [Published BioPortfolio - Jun 13 2013]
Have the “go bag” ready – killer days are here [Published Proactive Investors USA - Jun 12 2013]
BioTime raises $9.06 million in registered dire... [Published Individual.com - Jun 12 2013]
BioTime Appoints Henry L. Nordhoff to Board of ... [Published BioPortfolio - Jun 12 2013]
BioTime Appoints Henry L. Nordhoff to Board of ... [Published EON Science - Jun 12 2013]
BioTime Appoints Henry L. Nordhoff to Board of ... [Published Business Wire Health News - Jun 12 2013]
BioTime Secures $9 Million in Financing [Published Individual.com - Jun 12 2013]
Another hammering and EU human embryo patent is... [Published Proactive Investors USA - Jun 11 2013]
Running the bull… by the horns and the mouth [Published Proactive Investors USA - Jun 11 2013]
Stocks rebound as selling into strengths continue [Published Proactive Investors USA - Jun 11 2013]
HSBC ups Biostime (01112) target price to $62 [Published CCB International - Jun 11 2013]
This Metric Says You Are Smart to Sell Anacor P... [Published InsiderMonkey.com - Jun 10 2013]
BioTime Inc concludes USD9m financing [Published Individual.com - Jun 10 2013]
Report Published: "BioTime, Inc. (BTX) - Medica... [Published Live-PR.com - Jun 10 2013]
Arena Reports on Launch of BELVIQ (lorcaserin H... [Published BioMedReports - Jun 08 2013]
Stocks waiver as news withers [Published Proactive Investors USA - Jun 07 2013]
Stocks rebound, as sector perceptions deepen bu... [Published Proactive Investors USA - Jun 07 2013]
Thanks for yesterday, what can you do for me to... [Published Proactive Investors USA - Jun 07 2013]
BioTime (NYSE MKT: BTX) Closes on $9 M Financing [Published Proactive Investors USA - Jun 07 2013]
Summer of volatility ? [Published Proactive Investors USA - Jun 07 2013]
Stocks added to losses in a declining Wednesday... [Published Proactive Investors USA - Jun 07 2013]
Ah the dog days of summer… [Published Proactive Investors USA - Jun 07 2013]
BioTime (BTX) Closes on $9 Million Financing [Published BioSpace - Jun 07 2013]
BioTime, Inc. Closes on $9 Million Financing [Published EON Science - Jun 07 2013]

Blogs

sort by: Date \| Relevance
Once You Start Up Financings of the Fortnight, ... [Published The IN VIVO Blog - Jun 14 2013] Your faithful FOTF correspondent is in San Diego this week for the CalBIO conference, specifically to wax journalistic on a panel trying to look into the future – 2030! -- and opine sagely upon what we see. Some call this prediction; others call this ...
When Science Fiction Becomes Science Fact [Published Wall Street Pit - May 29 2013] Periodically, I forget that the rate of scientific change is accelerating exponentially. If you’re paying attention to the people who are actually pushing the scientific envelope, you will be astonished by the progress and the wealth it is creating. It ...
10 Stocks Making Big M&A News and Rumors This Week [Published Wall St. Cheat Sheet - May 25 2013] Here’s your Cheat Sheet to this week’s top mergers and acquisition news:Markets are at 5-year highs! Discover the best stocks to own. Click here for our fresh Feature Stock Pick now !Actavis ( NASDAQ:ACT ): Current price $127.31On Monday, it was announced ...
10 Stocks Making Big M&A News and Rumors This Week [Published Wall St. Cheat Sheet - May 25 2013] Here’s your Cheat Sheet to this week’s top mergers and acquisition news: Markets are at 5-year highs! Discover the best stocks to own. Click here for our fresh Feature Stock Pick now ! Actavis ( NASDAQ:ACT ): Current price $127.31 On Monday, it was ...
3 Merger and Acquisitions Stock Stories For a T... [Published Wall St. Cheat Sheet - May 23 2013] Elan Corporation ( NYSE:ELN ): Current price $12.39On Thursday, Elan announced that its board as decided that the privately-held investment firm Royalty Pharma’s revised offer as of May 20, to purchase all of Elan’s shares at $12.50 through its shell ...

Press Releases

sort by: Date \| Relevance
BioTime Appoints Henry L. Nordhoff to Board of ... [Published EON Science - Jun 12 2013]
BioTime Appoints Henry L. Nordhoff to Board of ... [Published Business Wire Health News - Jun 12 2013]
BioTime, Inc. Closes on $9 Million Financing [Published EON Science - Jun 07 2013]
BioTime, Inc. Closes on $9 Million Financing [Published Business Wire Health News - Jun 07 2013]
BioTime, Inc. to Raise $9 Million in Registered... [Published EON Science - Jun 03 2013]